Adverse effects of anticholinergic activity on cognitive functions in Alzheimer's disease

Kimiko Konishi, Koji Hori, Hiroyuki Uchida, Koichiro Watanabe, Itaru Tominaga, Masaki Kimura, Makoto Hosoyamada, Toshiaki Shibasaki, Akira Kataoka, Mitsugu Hachisu

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Elderly patients with Alzheimer's disease (AD) take more medicines, other than those for anti-dementia agents, than healthy people and are sensitive to anticholinergic medications. There are only a few reports, however, on the relationship between cognitive function and anticholinergic activity in AD patients, which is caused by taking prescribed medication. Methods: We measured serum anticholinergic activity (SAA) in 76 AD patients referred to a Psychogeriatric Unit and separated them into SAA positive group (n = 26, SAA (+) group) and SAA negative group (n = 50, SAA (-) group). The difference in demographic data and cognitive functions were compared between the two groups. Results and Conclusions: The total scores of the Mini-Mental State Examination (MMSE), the score of MMSE domain of registration and recall were significantly lower (P < 0.05) and the Functional Assessment Staging (FAST) score, the number of different kinds of prescribed psychotropic medications (the number of prescribed psychotropic medications) were significantly higher (P < 0.05) in the SAA (+) group than in the SAA (-). These results suggest that a higher number of psychotropic medications prescribed leads to a tendency for SAA to be positive and that anticholinergic activity accelerates Alzheimer's pathology and decreases cognitive function, especially memory in AD patients. We should more prudently prescribe psychotropic medications to AD patients, because the prescribed psychotropic medications are one of the important causes of decline in cognitive function of AD patients by way of anticholinergic activity.

Original languageEnglish
Pages (from-to)34-38
Number of pages5
JournalPsychogeriatrics
Volume10
Issue number1
DOIs
Publication statusPublished - 2010 Mar

Fingerprint

Cholinergic Antagonists
Cognition
Alzheimer Disease
Serum
Geriatric Psychiatry
Dementia
Demography
Pathology

Keywords

  • Alzheimers disease
  • Cognitive function
  • Mini-Mental State Examination
  • Psychotropic medications
  • Serum anticholinergic activity

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Gerontology
  • Medicine(all)

Cite this

Adverse effects of anticholinergic activity on cognitive functions in Alzheimer's disease. / Konishi, Kimiko; Hori, Koji; Uchida, Hiroyuki; Watanabe, Koichiro; Tominaga, Itaru; Kimura, Masaki; Hosoyamada, Makoto; Shibasaki, Toshiaki; Kataoka, Akira; Hachisu, Mitsugu.

In: Psychogeriatrics, Vol. 10, No. 1, 03.2010, p. 34-38.

Research output: Contribution to journalArticle

Konishi, K, Hori, K, Uchida, H, Watanabe, K, Tominaga, I, Kimura, M, Hosoyamada, M, Shibasaki, T, Kataoka, A & Hachisu, M 2010, 'Adverse effects of anticholinergic activity on cognitive functions in Alzheimer's disease', Psychogeriatrics, vol. 10, no. 1, pp. 34-38. https://doi.org/10.1111/j.1479-8301.2010.00310.x
Konishi, Kimiko ; Hori, Koji ; Uchida, Hiroyuki ; Watanabe, Koichiro ; Tominaga, Itaru ; Kimura, Masaki ; Hosoyamada, Makoto ; Shibasaki, Toshiaki ; Kataoka, Akira ; Hachisu, Mitsugu. / Adverse effects of anticholinergic activity on cognitive functions in Alzheimer's disease. In: Psychogeriatrics. 2010 ; Vol. 10, No. 1. pp. 34-38.
@article{8d9b57778b6e4e29a4cb078b76afdee0,
title = "Adverse effects of anticholinergic activity on cognitive functions in Alzheimer's disease",
abstract = "Background: Elderly patients with Alzheimer's disease (AD) take more medicines, other than those for anti-dementia agents, than healthy people and are sensitive to anticholinergic medications. There are only a few reports, however, on the relationship between cognitive function and anticholinergic activity in AD patients, which is caused by taking prescribed medication. Methods: We measured serum anticholinergic activity (SAA) in 76 AD patients referred to a Psychogeriatric Unit and separated them into SAA positive group (n = 26, SAA (+) group) and SAA negative group (n = 50, SAA (-) group). The difference in demographic data and cognitive functions were compared between the two groups. Results and Conclusions: The total scores of the Mini-Mental State Examination (MMSE), the score of MMSE domain of registration and recall were significantly lower (P < 0.05) and the Functional Assessment Staging (FAST) score, the number of different kinds of prescribed psychotropic medications (the number of prescribed psychotropic medications) were significantly higher (P < 0.05) in the SAA (+) group than in the SAA (-). These results suggest that a higher number of psychotropic medications prescribed leads to a tendency for SAA to be positive and that anticholinergic activity accelerates Alzheimer's pathology and decreases cognitive function, especially memory in AD patients. We should more prudently prescribe psychotropic medications to AD patients, because the prescribed psychotropic medications are one of the important causes of decline in cognitive function of AD patients by way of anticholinergic activity.",
keywords = "Alzheimers disease, Cognitive function, Mini-Mental State Examination, Psychotropic medications, Serum anticholinergic activity",
author = "Kimiko Konishi and Koji Hori and Hiroyuki Uchida and Koichiro Watanabe and Itaru Tominaga and Masaki Kimura and Makoto Hosoyamada and Toshiaki Shibasaki and Akira Kataoka and Mitsugu Hachisu",
year = "2010",
month = "3",
doi = "10.1111/j.1479-8301.2010.00310.x",
language = "English",
volume = "10",
pages = "34--38",
journal = "Psychogeriatrics",
issn = "1346-3500",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Adverse effects of anticholinergic activity on cognitive functions in Alzheimer's disease

AU - Konishi, Kimiko

AU - Hori, Koji

AU - Uchida, Hiroyuki

AU - Watanabe, Koichiro

AU - Tominaga, Itaru

AU - Kimura, Masaki

AU - Hosoyamada, Makoto

AU - Shibasaki, Toshiaki

AU - Kataoka, Akira

AU - Hachisu, Mitsugu

PY - 2010/3

Y1 - 2010/3

N2 - Background: Elderly patients with Alzheimer's disease (AD) take more medicines, other than those for anti-dementia agents, than healthy people and are sensitive to anticholinergic medications. There are only a few reports, however, on the relationship between cognitive function and anticholinergic activity in AD patients, which is caused by taking prescribed medication. Methods: We measured serum anticholinergic activity (SAA) in 76 AD patients referred to a Psychogeriatric Unit and separated them into SAA positive group (n = 26, SAA (+) group) and SAA negative group (n = 50, SAA (-) group). The difference in demographic data and cognitive functions were compared between the two groups. Results and Conclusions: The total scores of the Mini-Mental State Examination (MMSE), the score of MMSE domain of registration and recall were significantly lower (P < 0.05) and the Functional Assessment Staging (FAST) score, the number of different kinds of prescribed psychotropic medications (the number of prescribed psychotropic medications) were significantly higher (P < 0.05) in the SAA (+) group than in the SAA (-). These results suggest that a higher number of psychotropic medications prescribed leads to a tendency for SAA to be positive and that anticholinergic activity accelerates Alzheimer's pathology and decreases cognitive function, especially memory in AD patients. We should more prudently prescribe psychotropic medications to AD patients, because the prescribed psychotropic medications are one of the important causes of decline in cognitive function of AD patients by way of anticholinergic activity.

AB - Background: Elderly patients with Alzheimer's disease (AD) take more medicines, other than those for anti-dementia agents, than healthy people and are sensitive to anticholinergic medications. There are only a few reports, however, on the relationship between cognitive function and anticholinergic activity in AD patients, which is caused by taking prescribed medication. Methods: We measured serum anticholinergic activity (SAA) in 76 AD patients referred to a Psychogeriatric Unit and separated them into SAA positive group (n = 26, SAA (+) group) and SAA negative group (n = 50, SAA (-) group). The difference in demographic data and cognitive functions were compared between the two groups. Results and Conclusions: The total scores of the Mini-Mental State Examination (MMSE), the score of MMSE domain of registration and recall were significantly lower (P < 0.05) and the Functional Assessment Staging (FAST) score, the number of different kinds of prescribed psychotropic medications (the number of prescribed psychotropic medications) were significantly higher (P < 0.05) in the SAA (+) group than in the SAA (-). These results suggest that a higher number of psychotropic medications prescribed leads to a tendency for SAA to be positive and that anticholinergic activity accelerates Alzheimer's pathology and decreases cognitive function, especially memory in AD patients. We should more prudently prescribe psychotropic medications to AD patients, because the prescribed psychotropic medications are one of the important causes of decline in cognitive function of AD patients by way of anticholinergic activity.

KW - Alzheimers disease

KW - Cognitive function

KW - Mini-Mental State Examination

KW - Psychotropic medications

KW - Serum anticholinergic activity

UR - http://www.scopus.com/inward/record.url?scp=77956902883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956902883&partnerID=8YFLogxK

U2 - 10.1111/j.1479-8301.2010.00310.x

DO - 10.1111/j.1479-8301.2010.00310.x

M3 - Article

VL - 10

SP - 34

EP - 38

JO - Psychogeriatrics

JF - Psychogeriatrics

SN - 1346-3500

IS - 1

ER -